[4] In the SURMOUNT-1 obesity trial, a 72-week placebo-controlled study in 2,539 adults with obesity (without diabetes), mean weight change was 15.0%, 19.5%, and 20.9% at the 5, 10, and 15 mg doses versus 3.1% for placebo
There's this new category of stuff
Based on the response surface methodology-central composite design (RSM-CCD), an optimum formulation of SA-SMEDDS, consisting of ethyl oleate (oil, 12.30%), Cremophor-EL (surfactant, 66.25%), 1,2-propanediol (cosurfactant, 21.44%), and drug loading (50 mg/g), was obtained
short half life of GHK-Cu wherein 50 % is eliminated in less than 2 hrs makes the situation extremely challenging
Ongoing inflammatory conditions can affect B12 status